AI Article Synopsis
- The study examined COVID-19 patients from March-April and June-August 2020 in Marseille to identify changes in patient characteristics over time.
- Patients seen in June-August were significantly younger, more male, and had lower rates of hospitalization, ICU transfer, and mortality compared to those seen in March-April.
- Despite having a higher viral load in summer, patients had lower levels of severity markers, which correlated with a substantial reduction in lethality.
Article Abstract
Objective: To describe the characteristics of COVID-19 patients seen in March-April and June-August 2020 in Marseille, France with the aim to investigate possible changes in the disease between these two time periods.
Methods: Demographics, hospitalization rate, transfer to intensive care unit (ICU), lethality, clinical and biological parameters were investigated.
Results: Compared to those seen in March-April, COVID-19 patients seen in June-August were significantly younger (39.2 vs. 45.3 years), more likely to be male (52.9% vs. 45.6%), and less likely to be hospitalized (10.7 vs. 18.0%), to be transferred to ICU (0.9% vs. 1.8%) and to die (0.1% vs. 1.1%). Their mean fibrinogen and D-dimer blood levels were lower (1.0 vs. 1.5 g/L and 0.6 vs. 1.1 μg/mL, respectively). By contrast, their viral load was higher (cycle threshold ≤16 = 5.1% vs. 3.7%).
Conclusions: Patients in the two periods did not present marked age and sex differences, but markers of severity were undoubtedly less prevalent in the summer period, associating with a 10 times decrease in the lethality rate.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539893 | PMC |
| http://dx.doi.org/10.1016/j.ijid.2020.10.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) with rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) of 10-13 months. Patients with refractory disease fare worse, with a CR rate of 7% for subsequent therapies and median OS of 6 months.
View Article and Find Full Text PDFIntroduction: In France, over 90% of people living with HIV-1 (PLWH) achieve virological suppression with effective combination of antiretroviral therapies (ART), but limited data exist on the motivation for switching ART.
Objective: To describe the reasons and determinants for switching ART, with a particular focus on doravirine-based regimens, in routine clinical practice in France.
Design: This analysis of cross-sectional baseline data is part of the DoraVIH study, a French, multicenter (15 sites), two-step observational cohort study that includes prospective follow-up for a subset of participants.
Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128).
World J Urol
January 2025
Medical Oncology Department, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
Purpose: Surgery remains the cornerstone of localized renal cell carcinoma (RCC) care. Pembrolizumab has recently been recommended as a standard of care for RCC patients who are at high risk of recurrence. Data regarding the efficacy of ICIs either alone or in combination with ICIs or VEGF TKIs for VTT shrinkage are scarce.
View Article and Find Full Text PDFTungsten Diselenide Nanoparticles Produced via Femtosecond Ablation for SERS and Theranostics Applications.
Nanomaterials (Basel)
December 2024
Emerging Technologies Research Center, XPANCEO, Internet City, Emmay Tower, Dubai, United Arab Emirates.
Due to their high refractive index, record optical anisotropy and a set of excitonic transitions in visible range at a room temperature, transition metal dichalcogenides have gained much attention. Here, we adapted a femtosecond laser ablation for the synthesis of WSe nanoparticles (NPs) with diameters from 5 to 150 nm, which conserve the crystalline structure of the original bulk crystal. This method was chosen due to its inherently substrate-additive-free nature and a high output level.
View Article and Find Full Text PDFTooth Extraction as a Potential Risk Factor for Refractory Osteitis and Controversy of Using JAK Inhibitor to Alleviate Inflammation in SAPHO Syndrome.
Int J Rheum Dis
January 2025
Département Odontologie 3 Chemin des Maraîchers, Faculté de Santé, Université Toulouse III Paul Sabatier, Toulouse Cedex, France.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!